Boxer Capital Management’s Apogee Therapeutics APGE Stock Holding History

Boxer Capital Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.29M	Hold	70,000	–	–	0.7%	26
2026 Q1	$5.89M	Hold	70,000	–	–	0.77%	31
2025 Q4	$5.28M	Buy	70,000 +20,000	+40%	+$1.26M	1.16%	26
2025 Q3	$1.99M	Buy	+50,000	New	+$1.91M	0.63%	23
2025 Q1	–	Sell	-86,000	Closed	-$3.9M	–	29
2024 Q4	$3.9M	Buy	+86,000	New	+$4.39M	0.33%	44

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Boxer Capital Management's APGE Position: Q2 2026 in Review

Boxer Capital Management held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 70,000 shares worth $9.29M. The position accounts for 0.7% of the portfolio, ranked #26.

Boxer Capital Management first reported a position in APGE in Q4 2024 and has held it in 5 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Boxer Capital Management held 70,000 shares of Apogee Therapeutics worth $9.29M as of Q2 2026.
Boxer Capital Management left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up 0.7% of Boxer Capital Management's portfolio in Q2 2026, its #26 holding.
Boxer Capital Management first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 5 quarters since.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.